OPTIMA Oncology

Our vision is that every patient should have access to the most up-to-date individualised treatments and to innovative therapies. By strengthening shared decision-making based on dynamic computer-interpretable guidelines (CIGs), innovative broad data access and AI-driven technology and tools, we envision revolutionizing oncology care in Europe. OPTIMA is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 101034347. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views communicated within are those of OPTIMA. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.